FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of What Peptides Are Legal in the U.S.? Understanding FDA Approval, Compounding, and the Legal Gray Areas Holt Law